Trial Profile

EXT608 in Human Healthy Adults; A First-in-Human, Randomized, Double-Blind, Placebo-controlled, Single Dose Escalation Study

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 07 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs EXT 608 (Primary)
Indications Hyperparathyroidism
Focus Adverse reactions; First in man
Sponsors Extend Biosciences

Most Recent Events

06 Sep 2023 Status changed from recruiting to completed.
11 May 2023 According to Extend Biosciences Media Release,the study is nearing completion and a full data analysis is underway, with plans to present the results at an upcoming medical meeting.
11 May 2023 According to Extend Biosciences Media Release, the company look forward to rapidly advancing EXT608 into the phase 2a of clinical study.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com